Email: jameshejna -at- lif.kyoto-u.ac.jp
Office: Research Building #1, rm. 315
For Students: I am here as part of the Global Frontier in Life Science program, a Masters and Doctoral program conducted entirely in English. Part of my mission is to help you improve your scientific communication skills in English. In addition to teaching Bioscience courses in English, I am available for consultations on meeting abstracts, presentations, and so on when time permits.
I am currently recruiting students for a 1-credit course (seven 90-minute classes), Global Frontier in Life Science B, which will begin on Wednesday, Dec. 8, at 10:30 am, and will meet every Wednesday at that time, in the Science Frontier Laboratory Building, 1st floor small seminar room. The course will cover a wide range of current research topics, in journal club format, and the specific topics will be determined at the first class. This will be an opportunity to practice your English presentation skills while you stay current with bioscience outside of your narrow research focus. The course is designed for Masters students, but Doctoral students will be accepted if space is available. If interested, please directly join the class on Wednesday.
I recently arrived in Kyoto from Portland, Oregon, where I was involved in research for many years. Although I am no longer actively engaged in research, my primary interests revolve around genomic stability. Loss of genomic stability is a hallmark of cancer. Rare, recessive genetic diseases with a predisposition to cancer, such as Bloom Syndrome, Fanconi Anemia (FA), and Ataxia Telangiectasia, have defects in various DNA repair pathways, resulting in genomic instability. Isolation and characterization of the genes and their respective proteins from these rare diseases has provided important insights—not only about the respective rare diseases but the maintenance of genomic stability in normal cells. Overall, a more detailed knowledge of these DNA repair pathways may provide clues to novel treatments for these rare diseases, and also may suggest novel targets for cancer therapy.
Additional interests: Biosafety in the research lab.